CEO Luis Peña (Evommune)
January 7, 2021 09:27 AM ESTUpdated 02:12 PM
Startups
Deals

Der­mi­ra vets li­cense back can­di­dates from Eli Lil­ly to launch their own up­start

Nicole DeFeudis

Editor

About a year af­ter Eli Lil­ly ab­sorbed Der­mi­ra in a $1 bil­lion buy­out, the der­ma­tol­ogy com­pa­ny’s co-founders are li­cens­ing back three in­flam­ma­to­ry dis­ease pro­grams …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times